Effects of anti-G and anti-F antibodies on airway function after respiratory syncytial virus infection

American Journal of Respiratory Cell and Molecular Biology

Volumn 51, Issue 1, 2014, Pages 143-154

  Han, Junyan ^a   Takeda, Katsuyuki ^a   Wang, Meiqin ^a   Zeng, Wanjiang ^a   Jia, Yi ^a   Shiraishi, Yoshiki ^a   Okamoto, Masakazu ^a   Dakhama, Azzeddine ^a   Gelfand, Erwin W ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Airway; Anti respiratory syncytial virus F; Anti respiratory syncytial virus G; Inflammation; Respiratory syncytial virus

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; MONOCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS F MONOCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS G MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EOSINOPHILIA; IMMUNE RESPONSE; INFECTION PREVENTION; LUNG LAVAGE; LUNG RESISTANCE; MOUSE; NEWBORN INFECTION; NONHUMAN; PRIMARY INFECTION; REINFECTION; RESPIRATORY FUNCTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFECTION; SECONDARY INFECTION; THERAPY EFFECT; VIRUS REPLICATION;

AIRWAY; ANTI-RESPIRATORY SYNCYTIAL VIRUS-F; ANTI-RESPIRATORY SYNCYTIAL VIRUS-G; INFLAMMATION; RESPIRATORY SYNCYTIAL VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BRONCHIOLITIS, VIRAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MICE; MICE, INBRED BALB C; RESPIRATORY HYPERSENSITIVITY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84903694304     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0360OC     Document Type: Article

References (46)

1. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011;162:80-99.
2. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccin 2010;6:482-492.
3. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2010;2:655-661.
4. Oshansky CM, Zhang W, Moore E, Tripp RA. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol 2009;4:279-297.
5. Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, et al . Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998;178:1555-1561. (Pubitemid 28558122)
6. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 1998;72:2871-2880. (Pubitemid 28175524)
7. Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999;73:8485-8495. (Pubitemid 29441712)
8. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 1992;4:493-500.
9. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, et al. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci USA 2005;102:8996-9001. (Pubitemid 40881067)
10. Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 2006;176:1600-1608. (Pubitemid 43134304)
11. Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol 2003;77:6580-6584. (Pubitemid 36588431)
12. Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 1987;84:5625-5629.
13. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol 2001;22:602-607.
14. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001;2:732-738. (Pubitemid 32747163)
15. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009;183:6338-6345.
16. Han J, Takeda K, Okamoto M, Zeng W, Jia Y, Dakhama A, Gelfand EW. Comparison of the preventative, therapeutic, and prophylactic effects of anti-G and anti-F RSV glycoprotein antibodies in the response to primary and secondary RSV infection [abstract]. Am J Respir Crit Care Med 2011;183:A6206.
17. Dakhama A, Park JW, Taube C, Joetham A, Balhorn A, Miyahara N, Takeda K, Gelfand EW. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J Immunol 2005;175:1876-1883. (Pubitemid 41023094)
18. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-de ficient mice. J Exp Med 1997;186:449-454. (Pubitemid 27332903)
19. Mejías A, Chávez-Bueno S, Ríos AM, Saavedra-Lozano J, Fonseca Aten M, Hatfield J, Kapur P, Gómez AM, Jafri HS, Ramilo O. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004;48:1811-1822. (Pubitemid 38544394)
20. Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 1991;65:1634-1637.
21. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001;289:283-296. (Pubitemid 33141008)
22. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007;20:108-119. (Pubitemid 44967956)
23. Lukens MV, van de Pol AC, Coenjaerts FE, Jansen NJ, Kamp VM, Kimpen JL, Rossen JW, Ulfman LH, Tacke CE, Viveen MC, et al. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol 2010;84:2374-2383.
24. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest 1997;100:226-233. (Pubitemid 27311261)
25. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008;82:2040-2055. (Pubitemid 351293507)
26. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1: 398-401.
27. Radu GU, Caidi H, Miao C, Tripp RA, Anderson LJ, Haynes LM. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol 2010;84:9632-9636.
28. Mejías A, Chávez-Bueno S, Ríos AM, Aten MF, Raynor B, Peromingo E, Soni P, Olsen KD, Kiener PA, Gómez AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005;49:4700-4707. (Pubitemid 41552602)
29. Dakhama A, Lee YM, Gelfand EW. Virus-induced airway dysfunction: pathogenesis and biomechanisms. Pediatr Infect Dis J 2005;24:S159-S169, discussion S166-S167.
30. Smith PK, Wang SZ, Dowling KD, Forsyth KD. Leucocyte populations in respiratory syncytial virus-induced bronchiolitis. J Paediatr Child Health 2001;37:146-151. (Pubitemid 32398094)
31. van Schaik SM, Enhorning G, Vargas I, Welliver RC. Respiratory syncytial virus affects pulmonary function in BALB/c mice. J Infect Dis 1998;177:269-276. (Pubitemid 28063749)
32. Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, Anderson LJ. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009;200:439-447.
33. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, Oron A, Itskovich S, Ballin A, Houri S, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004;189:2057-2063. (Pubitemid 38692286)
34. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol 2009;22:147-161.
35. Fraticelli P, Sironi M, Bianchi G, D' Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107:1173-1181. (Pubitemid 32422914)
36. Amanatidou V, Sourvinos G, Apostolakis S, Tsilimigaki A, Spandidos DA. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 2006;25:410-414.
37. Bonduelle O, Duffy D, Verrier B, Combadière C, Combadière B. Cutting edge: protective effect of CX3CR1+ dendritic cells in a vaccinia virus pulmonary infection model. J Immunol 2012;188:952-956.
38. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butcher EC. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001;166:6477-6482. (Pubitemid 32467184)
39. Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health (Oxford) 2009;14:521-532.
40. Han J, Dakhama A, Jia Y, Wang M, Zeng W, Takeda K, Shiraishi Y, Okamoto M, Ziegler SF, Gelfand EW. Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand. J Allergy Clin Immunol 2012;130:1175-1186, e9.
41. Lee YM, Miyahara N, Takeda K, Prpich J, Oh A, Balhorn A, Joetham A, Gelfand EW, Dakhama A. IFN-gamma production during initial infection determines the outcome of reinfection with respiratory syncytial virus. Am J Respir Crit Care Med 2008;177:208-218.
42. Everard ML. The relationship between respiratory syncytial virus infections and the development of wheezing and asthma in children. Curr Opin Allergy Clin Immunol 2006;6:56-61. (Pubitemid 44517810)
43. Srikiatkhachorn A, Braciale TJ. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol 1997;71:678-685.
44. Boukhvalova MS, Prince GA, Blanco JC. Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity. J Virol 2007;81:9443-9450. (Pubitemid 47311487)
45. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261.
46. Li DQ, Zhang L, Pflugfelder SC, De Paiva CS, Zhang X, Zhao G, Zheng X, Su Z, Qu Y. Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4-dependent thymic stromal lymphopoietin/OX40 ligand/OX40 signaling pathways. J Allergy Clin Immunol 2011;128:1318-1325, e2.